Kashuba AD - Search Results

1

Corbett AH, Lim ML, Kashuba AD. Corbett AH, et al. Among authors: kashuba ad. Ann Pharmacother. 2002 Jul-Aug;36(7-8):1193-203. doi: 10.1345/aph.1A363. Ann Pharmacother. 2002. PMID: 12086554 Review.

2

Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline.

Corbett AH, Kashuba AD. Corbett AH, et al. Among authors: kashuba ad. Curr Opin Investig Drugs. 2002 Mar;3(3):384-90. Curr Opin Investig Drugs. 2002. PMID: 12054084

3

The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir.

Corbett AH, Eron JJ, Fiscus SA, Rezk NL, Kashuba AD. Corbett AH, et al. Among authors: kashuba ad. J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):921-8. doi: 10.1097/00126334-200408010-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15220698 Clinical Trial.

4

Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.

Lim ML, Min SS, Eron JJ, Bertz RJ, Robinson M, Gaedigk A, Kashuba AD. Lim ML, et al. Among authors: kashuba ad. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1034-40. doi: 10.1097/00126334-200408150-00006. J Acquir Immune Defic Syndr. 2004. PMID: 15247556 Clinical Trial.

5

Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women.

Min SS, Corbett AH, Rezk N, Cu-Uvin S, Fiscus SA, Petch L, Cohen MS, Kashuba AD. Min SS, et al. Among authors: kashuba ad. J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1577-80. doi: 10.1097/00126334-200412150-00008. J Acquir Immune Defic Syndr. 2004. PMID: 15577412

6

Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.

Kashuba AD, Tierney C, Downey GF, Acosta EP, Vergis EN, Klingman K, Mellors JW, Eshleman SH, Scott TR, Collier AC. Kashuba AD, et al. AIDS. 2005 Jan 28;19(2):145-52. doi: 10.1097/00002030-200501280-00006. AIDS. 2005. PMID: 15668539 Clinical Trial.

7

Drug-drug interactions and the pharmacotherapy of HIV infection.

Kashuba AD. Kashuba AD. Top HIV Med. 2005 Jun-Jul;13(2):64-9. Top HIV Med. 2005. PMID: 16082056 Free article. Review.

8

Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.

Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD. Yeh RF, et al. Among authors: kashuba ad. J Acquir Immune Defic Syndr. 2006 May;42(1):52-60. doi: 10.1097/01.qai.0000219774.20174.64. J Acquir Immune Defic Syndr. 2006. PMID: 16639344

9

Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir.

Corbett AH, Patterson KB, Tien HC, Kalvass LA, Eron JJ, Ngo LT, Lim ML, Kashuba AD. Corbett AH, et al. Among authors: kashuba ad. Antimicrob Agents Chemother. 2006 Aug;50(8):2756-61. doi: 10.1128/AAC.01006-05. Antimicrob Agents Chemother. 2006. PMID: 16870769 Free PMC article. Clinical Trial.

10

Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.

Hosseinipour MC, Corbett AH, Kanyama C, Mshali I, Phakati S, Rezk NL, van der Horst C, Kashuba AD. Hosseinipour MC, et al. Among authors: kashuba ad. AIDS. 2007 Jan 2;21(1):59-64. doi: 10.1097/QAD.0b013e3280117ca0. AIDS. 2007. PMID: 17148968 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

275 results

Search Page